Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cadonilimab Combined With Regorafenib for Patients With Hepatocellular Carcinoma Who Progressed on Systemic Therapy: An Open Label, Single Arm, Single Center, Prospective, Phase I/II Trial

NCT05773105 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05773105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05773105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cadonilimab Combined With Regorafenib for Patients With Hepatocellular Carcinoma Who Progressed on Systemic Therapy: An Open Label, Single Arm, Single Center, Prospective, Phase I/II Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 1/2
Overall status
Completed
Start date
September 19, 2023
Completion date
March 30, 2026
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma